HEC585: Clinical Trials

4 completed, 1 active not recruiting, 1 recruiting. 4 Phase 1, 1 Phase 2, 1 Phase 3.

By phase and status

Phase	Trials	Status
Phase 1	4	Completed 4
Phase 2	1	Active not recruiting 1
Phase 3	1	Recruiting 1

Follow HEC585: new trials by email Literature Review of HEC585 trials Research Report on HEC585

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF HEC585, Placebo, Pirfenidone - Idiopathic Pulmonary Fibrosis (IPF)	Phase 3	Recruiting	Sunshine Lake Pharma Co., Ltd.	472	2025-10-27	2026-04-21
Phase ll Study of HEC585 in Patients With IPF HEC585, Pirfenidone, Placebo - Idiopathic Pulmonary Fibrosis	Phase 2	Active not recruiting	Sunshine Lake Pharma Co., Ltd.	270	2021-06-30	2026-04-21
Study To Investigate The Potential DDI Between HEC585 And Pirfenidone/Nintedanib In Healthy Subjects HEC585, Nintedanib, Pirfenidone - Idiopathic Pulmonary Fibrosis	Phase 1	Completed	Sunshine Lake Pharma Co., Ltd.	33	2021-06-29	2026-05-15
To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy Volunteers HEC585, Pirfenidone, Nintedanib - Idiopathic Pulmonary Fibrosis	Phase 1	Completed	Sunshine Lake Pharma Co., Ltd.	33	2021-06-23	2022-05-19
Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC585 in Healthy Male and Female Subjects HEC585, placebo - Idiopathic Pulmonary Fibrosis	Phase 1	Completed	Sunshine Lake Pharma Co., Ltd.	72	2020-07-13	2022-03-15
The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects HEC585 - Idiopathic Pulmonary Fibrosis	Phase 1	Completed	Sunshine Lake Pharma Co., Ltd.	136	2017-05-20	2020-07-27

Conditions studied

Idiopathic Pulmonary Fibrosis (6)

Sponsors

Sunshine Lake Pharma Co., Ltd. (6)

Countries

China (5)  ·  United States (1)